Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jörg Frei is active.

Publication


Featured researches published by Jörg Frei.


Cancer Chemotherapy and Pharmacology | 1993

Pharmacological properties of the ornithine decarboxylase inhibitor 3-aminooxy-1-propanamine and several structural analogues

Helmut Mett; Jaroslav Stanek; Juan A. Lopez-Ballester; Juhani Jänne; Leena Alhonen; Riita Sinervirta; Jörg Frei; Urs Regenass

Analogues of 3-aminooxy-1-propanamine proved to be highly potent and selective inhibitors of ornithine decarboxylase (ODC). The compounds competed with ornithine for the substrate binding site of ODC, but resulted in progressive and apparently irreversible inactivation of the enzyme. Diamine oxidase was inhibited by these compounds to a lesser extent than ODC; the compounds were not metabolized by this enzyme. Several derivatives were growth-inhibitory for human T24 cells and for other mammalian cells, the most active compound being 3-aminooxy-2-fluoro-1-propanamine (AFPA). Growth-arrested cells were largely depleted of putrescine and spermidine. Cellular growth arrest could be antagonized by supplementation with spermidine. Selection for resistance against AFPA led to cells with amplified ODC genes and overexpression of the message. Some of the derivatives were tumoristatic at well-tolerated doses in mice bearing solid T24 tumours. The antiproliferative activity of these compounds appears to be mediated by polyamine depletion.


Archive | 1996

Pyrrolopyrimidines and processes for the preparation thereof

Peter Traxler; Guido Bold; Wolfgang Karl-Diether Brill; Jörg Frei


Archive | 1998

Phthalazines with angiogenesis inhibiting activity

Guido Bold; Jörg Frei; Peter Traxler; Karl-Heinz Altmann; Helmut Mett; David Stover; Jeanette Marjorie Wood


Journal of Medicinal Chemistry | 2000

New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis.

Guido Bold; Karl-Heinz Altmann; Jörg Frei; Marc Lang; Paul W. Manley; Peter Traxler; Bernhard Wietfeld; Josef Brüggen; Elisabeth Buchdunger; Robert Cozens; Stefano Ferrari; Pascal Furet; Francesco Hofmann; Georg Martiny-Baron; Johannes Rösel; Matthew A. Sills; David Stover; Figan Acemoglu; Eugen Boss; René Emmenegger; Laurent Lässer; Elvira Masso; Rosemarie Roth; Christian Schlachter; Werner Vetterli; Dominique Wyss; Jeanette Marjorie Wood


Archive | 1997

Fused pyrazole derivative and process for its preparation

Guido Bold; Jörg Frei; Marc Lang; Peter Traxler; Pascal Furet


Archive | 1996

Pyrazole derivatives and processes for the preparation thereof

Peter Traxler; Pascal Furet; Guido Bold; Jörg Frei; Marc Lang


Archive | 1997

Pyrrolopyrimidines and processes for their preparation

Peter Traxler; Jörg Frei; Guido Bold


Archive | 1997

Substituted pyrrolopyrimidines and processes for their preparation

Peter Traxler; Guido Bold; Marc Lang; Jörg Frei


Journal of Medicinal Chemistry | 1993

4-Amidinoindan-1-one 2'-amidinohydrazone : a new potent and selective inhibitor of S-adenosylmethionine decarboxylase

Jaroslav Stanek; Giorgio Caravatti; Jörg Frei; Pascal Furet; Helmut Mett; Peter Schneider; Urs Regenass


Archive | 1977

2-(3-Amino-2-hydroxy-propoxy)-pyrazines

Jörg Frei; Knut A. Jaeggi; Franz Ostermayer; Herbert Schroter

Collaboration


Dive into the Jörg Frei's collaboration.

Researchain Logo
Decentralizing Knowledge